Genmab and biontech expand global strategic collaboration to develop and commercialize novel immunotherapy candidates

Copenhagen, denmark--(business wire)--genmab a/s (nasdaq: gmab) and biontech se (nasdaq: bntx, “biontech”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. under the expansion, genmab and biontech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. since 2015, the companies have been working on the joint develop
BNTX Ratings Summary
BNTX Quant Ranking